MedTrace Logo

Study of ASN51 in Adults With Early Alzheimer's Disease

NCT06677203 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2025-06-29

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (PK), and preliminary effects on measures of clinical efficacy of multiple doses of ASN51 in adult participants with early Alzheimer's disease (AD).

Conditions

  • Alzheimer Disease

Interventions

DRUG

ASN51

Oral capsules

DRUG

Placebo

Oral capsules

Sponsors & Collaborators

  • Asceneuron S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-16
Primary Completion
2024-11-08
Completion
2024-11-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06677203 on ClinicalTrials.gov